These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 28629170)

  • 1. EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment.
    Keller S; Schmidt MHH
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28629170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.
    Eskilsson E; Rosland GV; Talasila KM; Knappskog S; Keunen O; Sottoriva A; Foerster S; Solecki G; Taxt T; Jirik R; Fritah S; Harter PN; Välk K; Al Hossain J; Joseph JV; Jahedi R; Saed HS; Piccirillo SG; Spiteri I; Leiss L; Euskirchen P; Graziani G; Daubon T; Lund-Johansen M; Enger PØ; Winkler F; Ritter CA; Niclou SP; Watts C; Bjerkvig R; Miletic H
    Neuro Oncol; 2016 Dec; 18(12):1644-1655. PubMed ID: 27286795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
    Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
    Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The EGFRvIII variant in glioblastoma multiforme.
    Gan HK; Kaye AH; Luwor RB
    J Clin Neurosci; 2009 Jun; 16(6):748-54. PubMed ID: 19324552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of EGFR-Met Interactions in the Pathogenesis of Glioblastoma and Resistance to Treatment.
    Guo G; Narayan RN; Horton L; Patel TR; Habib AA
    Curr Cancer Drug Targets; 2017; 17(3):297-302. PubMed ID: 28004613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme.
    Chistiakov DA; Chekhonin IV; Chekhonin VP
    Eur J Pharmacol; 2017 Sep; 810():70-82. PubMed ID: 28583430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFRvIII/integrin β3 interaction in hypoxic and vitronectinenriching microenvironment promote GBM progression and metastasis.
    Liu Z; Han L; Dong Y; Tan Y; Li Y; Zhao M; Xie H; Ju H; Wang H; Zhao Y; Zheng Q; Wang Q; Su J; Fang C; Fu S; Jiang T; Liu J; Li X; Kang C; Ren H
    Oncotarget; 2016 Jan; 7(4):4680-94. PubMed ID: 26717039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. F25P preproinsulin abrogates the secretion of pro-growth factors from EGFRvIII cells and suppresses tumor growth in an EGFRvIII/wt heterogenic model.
    Wei JW; Cui JQ; Zhou X; Fang C; Tan YL; Chen LY; Yang C; Liu M; Kang CS
    Cancer Lett; 2016 Sep; 380(1):1-9. PubMed ID: 27317648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In situ analysis of mutant EGFRs prevalent in glioblastoma multiforme reveals aberrant dimerization, activation, and differential response to anti-EGFR targeted therapy.
    Gajadhar AS; Bogdanovic E; Muñoz DM; Guha A
    Mol Cancer Res; 2012 Mar; 10(3):428-40. PubMed ID: 22232519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.
    An Z; Aksoy O; Zheng T; Fan QW; Weiss WA
    Oncogene; 2018 Mar; 37(12):1561-1575. PubMed ID: 29321659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme.
    Onishi M; Kurozumi K; Ichikawa T; Date I
    Neurol Med Chir (Tokyo); 2013; 53(11):755-63. PubMed ID: 24162241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting EGFRvIII for glioblastoma multiforme.
    Yang J; Yan J; Liu B
    Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme.
    Stockhausen MT; Broholm H; Villingshøj M; Kirchhoff M; Gerdes T; Kristoffersen K; Kosteljanetz M; Spang-Thomsen M; Poulsen HS
    Exp Cell Res; 2011 Jul; 317(11):1513-26. PubMed ID: 21514294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression.
    Micallef J; Taccone M; Mukherjee J; Croul S; Busby J; Moran MF; Guha A
    Cancer Res; 2009 Oct; 69(19):7548-56. PubMed ID: 19773446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.
    Choe G; Park JK; Jouben-Steele L; Kremen TJ; Liau LM; Vinters HV; Cloughesy TF; Mischel PS
    Clin Cancer Res; 2002 Sep; 8(9):2894-901. PubMed ID: 12231534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
    Ramnarain DB; Park S; Lee DY; Hatanpaa KJ; Scoggin SO; Otu H; Libermann TA; Raisanen JM; Ashfaq R; Wong ET; Wu J; Elliott R; Habib AA
    Cancer Res; 2006 Jan; 66(2):867-74. PubMed ID: 16424019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity.
    Lindberg OR; McKinney A; Engler JR; Koshkakaryan G; Gong H; Robinson AE; Ewald AJ; Huillard E; David James C; Molinaro AM; Shieh JT; Phillips JJ
    Oncotarget; 2016 Nov; 7(48):79101-79116. PubMed ID: 27738329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
    Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
    Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered.
    Gan HK; Cvrljevic AN; Johns TG
    FEBS J; 2013 Nov; 280(21):5350-70. PubMed ID: 23777544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of an EGFRvIII-JNK2-HGF/c-Met-Signaling Axis Required for Intercellular Crosstalk and Glioblastoma Multiforme Cell Invasion.
    Saunders VC; Lafitte M; Adrados I; Quereda V; Feurstein D; Ling Y; Fallahi M; Rosenberg LH; Duckett DR
    Mol Pharmacol; 2015 Dec; 88(6):962-9. PubMed ID: 26452771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.